"Melanoma cancer staging refers to TNM classification of primary cutaneous melanoma. The system does not apply to the primary non-cutaneous melanomas. The following article reflects the 8th edition manual published by the American Joint Committee on Cancer (AJCC), which has been used for staging since January 1, 2018 1."
"T1: ≤1 mm in maximum thickness recorded to nearest 0.1mm (not nearest 0.01 mm)"
"M1d: distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease"
"Stage is defined at different time points in the care of the cancer patient and are based on the continuum of assessment – Clinical (cTNM) – Pathological (pTNM) – Post therapy (ycTNM or ypTNM) – Recurrence (rTNM) and Autopsy (aTNM). A summary of the pathological stage (pTNM) is provided below."
"Stage is defined at different time points in the care of the cancer patient and are based on the continuum of assessment – Clinical (cTNM) – Pathological (pTNM) – Post therapy (ycTNM or ypTNM) – Recurrence (rTNM) and Autopsy (aTNM). A summary of the pathological stage (pTNM) is provided below."
"Stage is defined at different time points in the care of the cancer patient and are based on the continuum of assessment – Clinical (cTNM) – Pathological (pTNM) – Post therapy (ycTNM or ypTNM) – Recurrence (rTNM) and Autopsy (aTNM). A summary of the pathological stage (pTNM) is provided below."
"Stage is defined at different time points in the care of the cancer patient and are based on the continuum of assessment – Clinical (cTNM) – Pathological (pTNM) – Post therapy (ycTNM or ypTNM) – Recurrence (rTNM) and Autopsy (aTNM). A summary of the pathological stage (pTNM) is provided below."
"Treatment and prognosis:"
"IA ~ 99%"
"IB ~ 97%"
"IIA ~ 94%"
"IIB ~ 87%"
"IIC ~ 82%"
"IIIA ~ 93%"
"IIIB ~ 83%"
"IIIC ~ 69%"
"IV < 10%"
"Melanoma cancer staging refers to TNM classification of primary cutaneous melanoma. The system does not apply to the primary non-cutaneous melanomas. The following article reflects the 8th edition manual published by the American Joint Committee on Cancer (AJCC), which has been used for staging since January 1, 2018 1."
"Melanoma cancer staging refers to TNM classification of primary cutaneous melanoma. The system does not apply to the primary non-cutaneous melanomas. The following article reflects the 8th edition manual published by the American Joint Committee on Cancer (AJCC), which has been used for staging since January 1, 2018 1."
"TX: primary tumour thickness cannot be assessed"
"AJCC Prognostic Stage Groups"
"Primary tumour (T)"
"Regional lymph node (N)"
"Distant metastases (M)"
"AJCC Prognostic Stage Groups"
"Tis: melanoma in situ, including lentigo maligna and superficial spreading melanoma"
"T1a:"
"T1b:"
"T2a: >1.0-2.0 mm without ulceration"
"T2b: >1.0-2.0 mm with ulceration"
"T3a: >2.0-4.0 mm without ulceration"
"T3b: >2.0-4.0 mm with ulceration"
"T4a: >4.0 mm without ulceration"
"T4b: >4.0 mm with ulceration"
"N1a: one clinically occult node (i.e. detected by sentinel lymph node biopsy SLNB). No ITM/satellite/microsatellites"
"N1b: one clinically detected node. No ITM/satellite/microsatellites"
"N1c: no regional node disease but presence of in-transit (ITM), satellite, and/or microsatellite metastases"
"N2a: 2 or 3 clinically occult (i.e. detected by SLNB). No ITM/satellite/microsatellites"
"N2b: 2 or 3, at least 1 of which was clinically detected. No ITM/satellite/microsatellites"
"N2c: 1 clinically occult or clinically detected with presence of in-transit (ITM), satellite, and/or microsatellite metastases"
"N3a: ≥4 clinically occult (i.e. detected by SLNB). No ITM/satellite/microsatellites"
"N3b: ≥4, at least 1 of which was clinically detected, or presence of any number of matted nodes. No ITM/satellite/microsatellites"
"N3c: ≥2 clinically occult or clinically detected and/or presence of any number of matted nodes with presence of in-transit (ITM), satellite, and/or microsatellite metastases"
"M1a: distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node"
"M1a(0): LDH not elevated"
"M1a(1): LDH elevated"
"M1b: distant metastasis to lung with or without M1a sites of disease"
"M1b(0): LDH not elevated"
"M1b(1): LDH elevated"
"M1c: distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease"
"M1c(0): LDH not elevated"
"M1c(1): LDH elevated"
"M1d: distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease"
"M1c(0): LDH not elevated"
"M1c(1): LDH elevated"
"pT0-T3a; N1a-N2b; M0"
"pT0-T4b; N2b-N2c; M0"
Expected headings
"Primary tumour (T)"
"Regional lymph node (N)"
"Distant metastases (M)"
"Stage groups"
"AJCC Prognostic Stage Groups"
"Treatment and prognosis:"
"Stage is defined at different time points in the care of the cancer patient and are based on the continuum of assessment – Clinical (cTNM) – Pathological (pTNM) – Post therapy (ycTNM or ypTNM) – Recurrence (rTNM) and Autopsy (aTNM). A summary of the pathological stage (pTNM) is provided below."
"pT1a-T2a; N1a/N2a; M0"
"pT1a-T2a; N1a/N2a; M0"
"pT0-T3a; N1a-N2b; M0"
"pT0-T3a; N1a-N2b; M0"
"pT0-T4b; N2b-N2c; M0"
"pT0-T4b; N2b-N2c; M0"
"pT4b; N3a-N3c; M0"
"pT4b; N3a-N3c; M0"